AOD-9604: What Researchers Need to Know

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone, with an additional tyrosine residue at the C-terminus. It was developed by Monash University researchers to isolate the fat-metabolic properties of growth hormone without its growth-promoting, diabetogenic, or IGF-1-elevating effects. AOD-9604 holds the distinction of having received FDA GRAS (Generally Recognized as Safe) status.

Development Rationale

Full-length human growth hormone (191 amino acids) has well-documented fat-metabolic effects, but therapeutic use for obesity is limited by serious side effects: insulin resistance, joint pain, carpal tunnel syndrome, and potentially increased cancer risk via IGF-1 elevation. Researchers at Monash University hypothesized that the lipolytic activity resided in a specific region of the GH molecule, distinct from its growth-promoting domain.

Systematic fragment analysis identified amino acids 177-191 (the C-terminal region) as the active lipolytic fragment. The addition of a tyrosine residue enhanced stability and receptor interaction, producing the compound now known as AOD-9604.

Mechanism of Action

AOD-9604 stimulates fat metabolism through a dual mechanism: activating lipolysis (triglyceride breakdown in adipocytes) while simultaneously inhibiting lipogenesis (new fat synthesis). This bidirectional effect distinguishes it from compounds that only address one side of the fat storage equation.

Lipolytic Pathway

AOD-9604 activates beta-3 adrenergic receptor-mediated signaling in adipose tissue. This triggers hormone-sensitive lipase (HSL) activation, which cleaves stored triglycerides into free fatty acids and glycerol for oxidation. The mechanism mirrors the lipolytic action of full-length GH but operates independently of the GH receptor's growth-signaling domain.

Anti-Lipogenic Pathway

Concurrently, AOD-9604 inhibits fatty acid synthase activity and acetyl-CoA carboxylase, the rate-limiting enzymes in de novo lipogenesis. This prevents dietary carbohydrates and excess calories from being converted into new stored fat, creating a metabolic environment favoring net fat reduction.

What AOD-9604 Does NOT Do

The compound's selectivity profile is its defining feature:

Effect	Full-Length GH	AOD-9604
Fat metabolism	Yes	Yes
IGF-1 elevation	Yes (significant)	No
Insulin resistance	Yes (dose-dependent)	No
Muscle hypertrophy	Yes (via IGF-1)	No
Bone growth	Yes	No
Organ growth	Yes (acromegaly risk)	No
Water retention	Yes (common)	No
Carpal tunnel	Yes (common)	No

Clinical Trial History

AOD-9604 advanced further in the clinical pipeline than most research peptides:

• Phase 1: Established safety and tolerability in healthy volunteers. No serious adverse events. No impact on glucose metabolism or IGF-1 levels confirmed.
• Phase 2a: Demonstrated dose-dependent trends in body fat reduction in obese subjects over 12 weeks
• Phase 2b: Larger multi-center trial. Safety confirmed. Fat loss trends observed but primary efficacy endpoint (statistical significance vs placebo in overall weight loss) was not met
• FDA GRAS (2014): Received Generally Recognized as Safe designation for use as a food ingredient, confirming the safety profile established in clinical trials

Comparison to Other Fat-Loss Peptides

Compound	Mechanism	Primary Target	Side Effects
AOD-9604	GH-fragment lipolysis	Adipocyte beta-3 receptors	Minimal (GRAS status)
GLP-1 agonists	Appetite suppression + insulin	GLP-1 receptor (gut/brain)	Nausea, GI disturbance
5-Amino-1MQ	NNMT inhibition	NNMT enzyme in adipocytes	Under investigation
MOTS-c	AMPK activation	Mitochondrial energy expenditure	Under investigation
Tesamorelin	GHRH analog (GH release)	Pituitary GHRH receptor	Joint pain, edema

Research Considerations

AOD-9604 contains a disulfide bond between cysteine residues, making it susceptible to oxidation during storage. Researchers should protect reconstituted solutions from light, minimize freeze-thaw cycles, and store at 2-8°C. The disulfide bond is essential for biological activity; oxidized or misfolded AOD-9604 will show reduced efficacy in lipolysis assays. For handling protocols, see our storage and stability guide.

Key Research Context

Understanding the research context for AOD-9604: What Researchers Need to Know requires consideration of multiple factors including compound purity, experimental design, appropriate controls, and reproducibility standards. The scientific literature provides a foundation for evaluating the biological activity and potential applications of this compound category.

Research-grade compounds require rigorous quality verification before use in any experimental protocol. This includes confirming identity via mass spectrometry, verifying purity via HPLC chromatography (targeting ≥98% for definitive studies), and ensuring proper storage conditions have been maintained throughout the supply chain. A validated Certificate of Analysis from the supplier, ideally with third-party verification, is the minimum standard for quality assurance.

Experimental Design Considerations

Researchers should consider several practical factors when designing experiments with this compound. Dose-response curves should be established using at least three concentration points spanning the expected effective range. Vehicle controls must match the reconstitution buffer exactly. Time-course experiments help determine optimal treatment duration and peak effect windows. For in vivo studies, route of administration significantly affects bioavailability and tissue distribution patterns.

Proper reconstitution technique is essential for accurate dosing. Always inject diluent slowly along the vial wall rather than directly onto the lyophilized cake. Gentle swirling (never vortexing or shaking) prevents aggregation and denaturation. Use bacteriostatic water for multi-dose vials and sterile water for single-use preparations. Record the reconstitution date, concentration, and storage conditions for each vial.

Literature and Evidence Standards

When evaluating the research evidence for any peptide compound, consider the hierarchy of evidence: randomized controlled clinical trials provide the strongest evidence, followed by controlled preclinical studies in validated animal models, then in vitro cell culture studies, and finally computational or theoretical analyses. The number of independent research groups replicating findings, publication in peer-reviewed journals, and consistency of results across different experimental systems all contribute to the overall evidence quality assessment.

Researchers should also be aware of publication bias (positive results are more likely to be published than negative results) and the importance of proper statistical analysis in interpreting study outcomes. Effect sizes, confidence intervals, and appropriate statistical tests are as important as p-values in evaluating research significance. For a comprehensive understanding of peptide quality metrics, review our guide on what 98% purity means and how to interpret analytical data from qualified suppliers.

Methodological Framework

Rigorous research methodology is essential for generating reliable data with any research compound. The following framework outlines best practices for experimental design, quality control, and data interpretation that apply to studies involving this compound category.

Quality Control Protocol

Before initiating any experimental protocol, verify the compound identity and purity through independent analytical testing. The minimum verification standard includes reversed-phase HPLC analysis confirming ≥98% purity and mass spectrometry confirming the correct molecular weight within ±1 Da of the theoretical value. For compounds with disulfide bonds or metal coordination (such as copper peptides), additional analytical methods may be required to confirm proper folding or complexation. Document the lot number, vendor, CoA reference, and storage conditions for every compound used in research.

Dose-Response Characterization

Establishing a complete dose-response curve is fundamental to characterizing any bioactive compound. Use a minimum of five concentration points spanning at least two logarithmic orders of magnitude. Include both sub-threshold and supra-maximal concentrations to define the full response range. Calculate EC50 (half-maximal effective concentration) values using nonlinear regression with appropriate curve-fitting models. For in vivo studies, allometric scaling from published animal data provides initial dose estimates, but species-specific pharmacokinetic differences necessitate empirical dose optimization.

Controls and Replication

Every experiment requires appropriate controls: vehicle controls (matching the reconstitution buffer composition exactly), positive controls (a compound with known activity in the assay system), and negative controls (untreated or inactive analog). Biological replicates (independent experiments on different days with different cell passages or animal cohorts) are more informative than technical replicates (repeated measurements of the same sample). A minimum of three biological replicates is standard for publication-quality data. Statistical analysis should include measures of central tendency, variability (standard deviation or standard error), and appropriate hypothesis testing with correction for multiple comparisons where applicable.

Safety and Handling

All research compounds should be handled according to standard laboratory safety protocols. Wear appropriate personal protective equipment (gloves, lab coat, eye protection) when handling lyophilized powders and reconstituted solutions. Avoid inhalation of lyophilized powder during reconstitution. Dispose of unused compound and contaminated materials according to institutional biosafety and chemical waste guidelines. Research peptides are intended for laboratory research use only and are not approved for human therapeutic use unless specifically noted (such as FDA-approved compounds like Tesamorelin).

Proper storage extends compound viability and ensures consistent experimental results. Lyophilized compounds should be stored at -20°C with desiccant in sealed containers. After reconstitution with bacteriostatic water, store at 2-8°C and use within the validated stability window (typically 3-4 weeks). For long-term storage of reconstituted solutions, prepare single-use aliquots and freeze at -20°C to avoid repeated freeze-thaw cycles that accelerate degradation.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) designed to retain fat-metabolic activity without growth-promoting or diabetogenic effects. It has FDA GRAS status.

Does AOD-9604 increase IGF-1?

No. AOD-9604 does not elevate IGF-1 levels, stimulate muscle growth, affect bone growth, or cause insulin resistance. Its activity is selective to fat metabolism pathways.

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. This article is intended for educational and informational purposes only. It does not constitute medical advice. Last updated: April 20, 2026.